SCHEMBL22040965

SCHEMBL22040965

Nc1cnccc1OC1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 6/20 0.40
CHUK O15111 4/20 0.40
AOC1 P19801 2/20 0.38
AOC3 Q16853 2/20 0.38
ROCK1 Q13464 4/20 0.37
MKNK1 Q9BUB5 3/20 0.37
MKNK2 Q9HBH9 3/20 0.37
LCK P06239 2/20 0.37
GAA P10253 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
KDM6B O15054 1/20 0.36
KDM4A O75164 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4D Q6B0I6 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31342868 1.00 IKBKB (0.40) IKBKBCHUKAOC1AOC3ROCK1
SCHEMBL15779202 0.93 MKNK1 (0.43) IKBKBCHUKAOC1AOC3ROCK1
SCHEMBL30309967 0.93 MKNK1 (0.44) IKBKBCHUKAOC1AOC3ROCK1
SCHEMBL15784002 0.93 MKNK1 (0.44) IKBKBCHUKAOC1AOC3ROCK1
SCHEMBL18860141 0.92 MCHR1 (0.47) IKBKBCHUKAOC1AOC3ROCK1
SCHEMBL21013756 0.92 MCHR1 (0.47) IKBKBCHUKAOC1AOC3ROCK1
SCHEMBL15779265 0.91 MKNK1 (0.45) IKBKBCHUKAOC1AOC3MKNK1
SCHEMBL28447994 0.90 IKBKB (0.37) IKBKBCHUKAOC1AOC3ROCK1
SCHEMBL19943509 0.89 PDE10A (0.42) IKBKBCHUKAOC1AOC3ROCK1
SCHEMBL15779034 0.88 ATR (0.43) IKBKBCHUKATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 US disclosed
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 US disclosed
US-11053241-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-07-06 US disclosed
US-20200172540-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-06-04 US disclosed
WO-2020112937-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834449-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 IKBKB 298/4885CHUK 151/4885AOC1 4648/4885
US-11053241-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 IKBKB 298/4885CHUK 151/4885AOC1 4648/4885
US-20200172540-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 IKBKB 298/4885CHUK 151/4885AOC1 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.